New insights into the pathogenesis and management of steroid-resistant asthma

Journal of Asthma

Volumn 34, Issue 3, 1997, Pages 177-194

  Spahn, Joseph D ^a,b   Leung, Donald Y M ^b   Szefler, Stanley J ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; STEROID;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; DNA BINDING; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; LIGAND BINDING; PATHOGENESIS; PATIENT MONITORING; PEAK EXPIRATORY FLOW; REVIEW;

EID: 0030986205     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.3109/02770909709068188     Document Type: Review

References (150)

1. Hench PS, Kendall EC, Slocomb CH, Polley HF: The effect of a hormone of the adrenal cortex (17-hydroxy- 11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis; preliminary report. Proc Staff Meet Mayo Clin 24: 181 (1949).
2. Randolph TG, Randolph, Rollins JP: The effect of cortisone on bronchial asthma. J Allergy 21: 288-295 (1950).
3. Carryer HM, Koelsche GA, Prickman LE, Maytum CK, Lake C, Williams HL: The effect of cortisone on bronchial asthma and hay fever occurring in subjects sensitive to ragweed pollen. J Allergy 21: 282-287 (1950).
4. Feinberg SM, Dannenberg TB, Malkiel S: ACTH and cortisone in allergic manifestations: Therapeutic results and studies on immunological and tissue reactivity. J Allergy 22: 195-210 (1951).
5. Szefler S: Glucocorticoid therapy for asthma: Clinical pharmacology. J Allergy Clin Immunol 88: 147-165 (1991).
6. Dunhill MS: The pathology of asthma with special reference to changes in the bronchial mucosa. J Clin Pathol 13: 27-33 (1960).
7. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T: Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 131: 599-606 (1985).
8. Robinson DS, Hamid Q, Ying S, Tiscopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326: 298-304 (1992).
9. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, Michel F-B: Eosinophilic inflammation in asthma. N Engl J Med 323:1033-1039 (1990).
10. Smith DF, Toft DO: Steroid receptors and their associated proteins. Mol Endocrinol 7: 4-11 (1993).
11. Ku Tai PK, Albers MW, Chang H, Farber LE, Schreiber SL: Association of a 59 kd immunophilin with the glucocorticoid receptor complex. Science 256:1315-1318 (1992).
12. Picard D, Yamomoto KR: Two signals mediate hormone dependent nuclear localization of the glucocorticoid receptor. EMBO J 6:3333-3340 (1987).
13. Tsai SY, Carlstedt-Duke J, Weigel NL, Dahlman K, Gustafsson JA, Tsai MJ, et al: Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell 55: 361-369 (1988).
14. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Siegler PB: Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352: 497-505 (1991).
15. Sakai DD, Helms S, Carlstedt-Duke J, Gustafsson JA, Rottman FM, Yamamoto KR: Hormone-mediated repression of transcription: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev 2:1144-1154 (1988).
16. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR: Transcription factor interactions: Selectors of positive or negative regulation from a single DNA element. Science 249:1266-1272 (1990).
17. Yang-Yen H-F, Chambard J-C, Sun Y-L, Smeal T, Schmidt TJ, Drouin J, Karin M: Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62:1205-1215 (1990).
18. Barnes PJ, Greening AP, Crompton GK: Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 152: S125-S142 (1995).
19. Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, Verma IM, Evans R: Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62:1217-1226 (1990).
20. Adcock IM, Brown CR, Gelder CM, Shirasaki H, Peters MJ, Barnes PJ: The effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol 37: C331-338 (1995).
21. Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 91: 752-756 (1994).
22. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS: Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270: 283-286 (1995).
23. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 270: 286-290 (1995).
24. Peppel K, Vinci JM, Baglioni C: The AU-rich sequences in the 3′ untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids. J Exp Med 173: 349-355 (1991).
25. Hegele RG, Hogg JC: The pathology of asthma: An inflammatory disorder. In Severe Asthma: Pathogenesis and Clinical Management (Szefler SJ, Leung DYM, editors), Marcel Dekker, New York, 1996, 61-76.
26. Borish L, Mascali JJ, Dishuck J, Beam WR, Martin RJ, Rosenwasser LJ: Detection of alveolar macrophage- derived IL-1β in asthma: inhibition with corticosteroids. J Immunol 149:3078-3082 (1992).
27. Boumpas DT, Older SA, Anastassiou ED, Tsokos GC. Nelson D, Balow JE: Dexamethasone inhibits human IL-2 but not IL-2R gene expression in vitro at the level of nuclear transcription. J Clin Invest 87:1739-1747 (1991).
28. Culpepper JA, Lee F: Regulation of IL-3 expression by glucocorticoids in cloned murine T lymphocytes. J Immunol 135:3191-3197 (1985).
29. Wu CY, Fargeas C, Nakajima T, Delespesse G: Glucocorticoids suppress the production of interleukin 4 by human lymphocytes. Eur J Immunol 21:2645-2647 (1991).
30. Byron KA, Varigos G, Wooton A: Hydrocortisone inhibition of human interleukin-4. Immunology 77: 624-626 (1992).
31. Rolfe FG, Hughes JM, Armour CL, Sewell WA: Inhibition of interleukin-5 gene expression by dexamethasone. Immunology 77: 494-499 (1992).
32. Robinson D, Hamid Q, Ying S, Bentley A, Assoufi B, Durham, Kay AB: Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-γ cytokine gene expression. Am Rev Respir Dis 143: 401- 406 (1993).
33. Tobler A, Meier R, Seitz M, Dewald B, Baggiolini M, Fey MF: Glucocorticoids downregulate gene expression of GM-CSF, NAP-1, IL-8, IL-6, but not M-CSF in human fibroblasts. Blood 79: 45-51 (1992).
34. Kato M, Schleimer RP: Antiinflammatory steroids inhibit granulocyte/macrophage colony stimulating factor production by human lung tissue. Lung 172: 113-124 (1994).
35. Waage A, Bakke O: Glucocortiocoids suppress the production of tumor necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 63: 299-302 (1988).
36. Sanderson CJ: Interleukin-5, eosinophils, and disease. Blood 79:3101-3109 (1992).
37. Clutterbuck EJ, Hirst EMA, Sanderson CJ: Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73:1504-1512 (1989).
38. Busse WW, Sedwick JB, Jarjour NN, Calhoun WJ: Eosinophils and basophils in allergic airway inflammation. J Allergy Clin Immunol 94:1250-1254 (1994).
39. Rothman P, Lutzker S, Cook W, Coffman R, Alt FW: Mitogen plus interleukin 4 induction of Ce transcripts in B lymphoid cells. J Exp Med 165:2385-2389 (1988).
40. Stavnezer J, Raddiffe G, Lin YC, Nietupski J, Berggren L, Sitia R, Severinson E: Immunoglobulin heavy-chain switching may be directed by prior induction of transcripts from constant-region genes. Proc Natl Acad Sci USA 85:7704-7708 (1988).
41. Bochner BS, Luscinskas FW, Gimbrone MA, Newman W, Sterbinsky SA, Derse-Anthony CP, Klunk D, Schleimer RP: Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 173:1553-1556 (1991).
42. Thornhill MH, Kyan-Aung U, Haskard DO: IL-4 increases human endothelial cell adhesiveness for T cells but not neutrophils. J Immunol 144:3060-3065 (1990).
43. Bochner BS, Peachell PT, Brown KE, Schleimer RP: Adherence of human basophils to cultured umbilical vein endothelial cells. J Clin Invest 81:1355-1364 (1988).
44. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissman G: A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 89:9991-9995 (1992).
45. Kaiser J, Bickel CA, Bochner BS, Schleiner RP: The effects of the potent glucocorticoid budesonide on adhesion of eosinophils to human vascular endothelial cells and on endothelial expression of adhesion molecules. J Pharmacol Exp Ther 267: 245-249 (1993).
46. 4 by purified human neutrophils. J Pharmacol Exp Ther 250:598-605 (1989).
47. Henderson WR: Eicosanoids and lung inflammation. Am Rev Respir Dis 135:1176-1185 (1987).
48. James AL, Pare PD, Hogg JC: The mechanics of airway narrowing in asthma. Am Rev Respir Dis 139: 242- 246 (1989).
49. Lam S, CHan H, LeRichie JC, Chan-Yeung M, Salari H: Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 81: 711-717 (1988).
50. Murray JJ, Tonnel AB, Brash AR, Roberts LJ, Gosset P, Workman R, Capron A, Oates JA: Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med 315: 800-804 (1986).
51. O'Driscoll BRC, Cromwell O, Kay AB: Sputum leukotrienes in obstructive airways diseases. Clin Exp Immunol 55: 397-4104 (1984).
52. Isono T, Koshihara, Murota S, Fukuda Y, Furukawa S: Measurement of immunoreactive leukotriene C4 in blood of asthmatic children. Biochem Biophys Res Commun 130:486492 (1985).
53. Hong S-CL, Levine L: Inhibition of arachadonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids. Proc Natl Acad Sci USA 73:1730-1734 (1976).
54. Balter MS, Eschenbacher WL, Peters-Golden M: Arachadonic acid metabolism in cultured alveolar macrophages from normal, atopic, and asthmatic subjects. Am Rev Respir Med 138:1134-1142 (1988).
55. Sebaldt RJ, Sheller JR, Oates JA, Roberts LJ, Fitzgerald GA: Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci USA 87:6974- 6978 (1990).
56. Dworski R, Fitgerald GA, Oates JA, Sheller JR: Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 149: 953- 959 (1994).
57. Balter MS, Eschenbacher WL, Peters-Golden M: Arachadonic acid metabolism in cultured alveolar macrophages from normal, atopic, and asthmatic subjects. Am Rev Respir Med 138:1134-1142 (1988).
58. Boschetto P, Rogers DF, Fabbri M, Barnes PJ: Corticosteroid inhibition of airway microvascular leakage. Am Rev Respir Dis 143: 605-609 (1991).
59. Schwartz HJ, Lowell FC, Melby JC: Steroid resistance in bronchial asthma. Ann Intern Med 69: 493-499 (1968).
60. Carmichael J, Paterson IC, Diaz P, Crompton GK, Day AB Grant IWB: Corticosteroid resistance in chronic asthma Br Med J 282:1419-1422 (1981).
61. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai J-J, Frew AJ, Kay AB: Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 144:1016-1025 (1991).
62. Sher ER, Leung DYM, Surs W, Kam JC, Zieg G, Kamada AK, Szefler SJ: Steroid resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 93 : 33-39 (1994).
63. Alvarez J, Surs WK, Leung DYM, Ikle D, Gelfand EW, Szefler SJ: Steroid-resistant asthma: Immunologic and pharmacologic features. J Allergy Clin Immunol 89: 714-721 (1992).
64. Poznansky M, Gordon ACH, Douglas JG, Krajewski AS, Wyllie AH, Grant IAB: Resistance to methylprednisolone in cultures of blood mononuclear cells from glucocorticoid-resistant asthmatic patients. Clin Sci 67: 6 39-645 (1984).
65. Corrigan CJ, Brown PH, Barnes NC, Tsai J-J, Frew AJ, Kay AB: Glucocorticoid resistance in chronic asthma. Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A. Am Rev Respir Dis 144:1026-1032 (1991).
66. Matusiewicz SP, Brown PH, Wallace WAH, Ramage E, Howie SEM, Crompton GK, Greening AP: Bronchial mucosal inflammation in patients with corticosteroid sensitive and corticosteroid resistant chronic asthma. Thorax 48:1060-1061 (1993) (abstract).
67. Wilkinson JRW, Crea AEG, Clark TJH, Lee TH: Identification and characterization of monocyte-derived neutrophil-activating factor in corticosteroid-resistant bronchial asthma. J Clin Invest 84:1930-1941 (1989).
68. Lane SJ, Sousa AR, Poston RN, Lee TH: In vivo cutaneous tuberculin response to prednisolone in corticosteroid resistant bronchial asthma. J Allergy Clin Immunol 91: 222 (1993) (abstract).
69. Lane SJ, Arm JP, Staynov DZ, Lee TH: Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma. Am J Respir Cell Mol Biol 11: 42-48 (1994).
70. Sher ER, Leung DYM, Surs W, Kam JC, Zieg G, Kamada AK, Szefler SJ: Steroid resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 93: 33-39 (1994).
71. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DYM: Combination IL-2 and IL-4 reduces glucocorticoid receptor binding affinity and T cell response to glucocorticoids. J Immunol 151:3460-3466 (1993).
72. Adcock IA, Lane SJ, Brown CR, Peters MJ, Lee TH, Barnes PJ: Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 154:3500-3505 (1995).
73. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ: Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 182:1951-1958 (1995).
74. Klemm DJ, Surs W, Spahn JD, Szefler SJ, Leung DYM: Alterations in glucocorticoid receptor binding to DNA contributes to steroid resistant asthma. J Allergy Clin Immunol 97: 361A (1996) (abstract).
75. Bamberger CM, Bamberger A-M, de Castro M, Chrousos GP: Glucocorticoid receptor β, a potential inhibitor of glucocorticoid action in humans. J Clin Invest 95:2435-2441 (1995).
76. Expert Panel Report, National Heart, Lung, and Blood Institute, National Asthma Education Program. Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, Bethesda, MD, 1991, Publication No. 91-3042.
77. Martin ME, Grunstein MM, Larsen GL: The relationship of gastroesophageal reflux to nocturnal wheezing in children. Ann Allergy 49: 318-322 (1982).
78. Alien CJ, Newhouse MT: Gastroesophageal reflux and chronic respiratory disease. Ann Rev Respir Dis 129: 645-647 (1984).
79. Boyle JT, Tuchman DN, Altschuler SM, Nixen TE, Pack AI, Cohen S: Mechanisms for the association of gastroesophageal reflux and bronchospasm. Am Rev Respir Dis 131: S16-20 (1985).
80. Irwin RS, Curley FJ, French CL: Difficult-to-control asthma: contributing factors and outcome of a systematic management protocol. Chest 103:1662-1669 (1993).
81. Bostwick HE, Glassman MS: Gastroesophageal reflux-associated pulmonary disease in infants and children. Am J Asthma Pediatr 3: 209-214 (1990).
82. Berquist WE, Rachelefsky GS, Kadden M, Siegel SC, Katz RM, Fonkalsrud EW, Ament ME: Gastroesophageal reflux-associated recurrent pneumonia and chronic asthma in children. Pediatrics 68: 29-35 (1981).
83. Rachelefsky GS, Katz RM, Siegel SC: Chronic sinus disease with associated reactive airway disease in children. Pediatrics 73: 526-529 (1984).
84. Rachelefsky GS, Goldberg M, Katz RM, Boris G, Gyepes MT, Shapiro MJ, Mickey MR, Finegold SM, Siegel SC: Sinus disease in children with respiratory disease. J Allergy Clin Immunol 61: 310-314 (1978).
85. McAlister WH, Lusk R, Muntz HR: Comparison of plain radiographs and coronal CT scans in infants and children with recurrent sinusitis. Am J Radiol 153:1259-1264 (1989).
86. International Consensus Report on Diagnosis and Treatment of Asthma. National Heart, Lung, and Blood Institute, National Institutes of Health, 1992, Publication No. 92-3091.
87. Rand CS, Wise RA, Nides M, Simmons MS, Bleecker ER, Kusek JW, Li VC, Tashkin DP: Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 146:1559-1564 (1992).
88. Anderson RJ, Kirk LM: Methods of improving patient compliance in chronic disease states. Arch Intern Med 142:1673-1675 (1982).
89. Mellins RB, Zimmerman B, Clark NM: Patient compliance: Are we wasting our time and we don't know it? Am Rev Respir Dis 146:1376-1377 (1992) (editorial).
90. Spahn JD, Leung DYM, Surs W, Harbeck RJ, Nimmagadda S, Szefler SJ: Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am J Respir Crit Care Med 151:1709-1714 (1995).
91. Cameron SJ, Cooper ET, Crompton GK, Hoare MV, Grant I: Substitution of beclomethasone aerosol for oral prednisoline in the treatment of chronic asthma. Br Med J 4: 205-207 (1973).
92. Tarlo SM, Broder I, Davies GM: Six-month double- blind, controlled trial of high dose, concentrated beclomethasone diproprionate in the treatment of severe asthma. Chest 93: 998-1002 (1988).
93. Whelan AM, Hahn NW: Optimizing drug delivery from metered-dose inhalers. DICP. Ann Pharmacother 25: 638-645 (1991).
94. Newman SP: Therapeutic aerosols. In Aerosols and the Lung: Clinical and Experimental Aspects (Clarke SW, Pavia D, editors), Butterworths, London, 1984, 197-224.
95. Toogood JH, Jennings B, Baskerville J, Johansson S-A: Clinical use of spacer systems for corticosteroid inhalation therapy: A preliminary analysis. Eur J Respir Dis 63: 100-107 (1982).
96. Hill MR, Szefler SJ, Ball BB, Bartoszek M, Brenner AM: Monitoring glucocorticoid therapy: A pharmacokinetic approach. Clin Pharmacol Ther 48: 390-398 (1990).
97. Bartoszek M, Brenner AM, Szefler SJ: Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 42: 424-432 (1987).
98. Bergrem H, Refvem OK: Altered prednisolone pharmacokinetics in patients treated with rifampicin. Acta Med Scand 213: 339-343 (1983).
99. Udwadia ZF, Sridhar G, Beveridge CJ, Soutar C, McHardy GJR, Leitch AG: Catastrophic deterioration in asthma induced by rifampicin in steroid-dependent asthma. Respir Med 87: 629 (1993).
100. Jubiz W, Meikle AW: Alterations of glucocorticoid actions by other drugs and disease states. Drugs 18: 113-121 (1979).
101. Sears MR, Taylor DR, Print CG., Lake DC, Quingquing L, Flannery EM. Yates DM, Lucas MK, Herbison GP: Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336:1391-1396 (1990).
102. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habrick B, Cockcroft D, Boivin J-F, McNutt M, Buist AS, Reebuck AS: The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326: 501-506 (1992).
103. Woolcock AJ: Steroid resistant asthma: What is the clinical definition? Eur Respir J 6:743-747 (1993).
104. Peters MJ, Adcock IM, Brown CR, Barnes PJ: β-agonist inhibition of steroid-receptor DNA binding activity in human lung. Am Rev Respir Dis 147: A772 (1993) (abstract).
105. Stevens DA, Barnes PJ, Adcock IM: β-agonists inhibit DNA binding of glucocorticoid receptors in human pulmonary and bronchial epithelial cells. Am J Respir Crit Care Med 151: A195 (1995) (abstract).
106. Platts-Mills, TAE, Mitchell EB, Nock P, Tovey ER, Moszoro H, Wilkens SR: Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet 2: 675-678 (1982).
107. Simon HU, Grotzer M, Nikolaizik WH, Blaser K, Schoni MH: High altitude climate therapy reduces peripheral blood T lymphocyte activation, eosinophilia and bronchial obstruction in children with house-dust mite allergic asthma. Pediatr Pulmonol 17: 304-311 (1994).
108. Bye MR, Kerstein D, Barsh E: The importance of spirometry in the assessment of childhood asthma. Am J Dis Child 146: 977-978 (1992).
109. Martin RJ, Blager FB, Gay M, Wood RP: Paradoxic vocal cord motion in presumed asthmatics. Semin Respir Med 8: 332-337 (1987).
110. Szefler SJ: Alternative therapy in severe asthma: Rationale and guidelines for applications. Update No. 11. Allergy Principles and Practice, 3rd ed, (Middleton E Jr, Reed CE, Ellis EF, Adkinson NF, Yuninger JW, editors), CV Mosby, St. Louis, 1991.
111. Noonan M, Chervinsky P, Busse WW, Weisberg SC, Pinnas J, De Boisblanc BP, Boltansky H, Pearlman D, Repsher L, Kellerman D: Fluticasone proprionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 152:1467-1473 (1995).
112. Spahn JD, Landwehr LP, Surs W, Leung DYM, Szefler SJ: Effects of glucocorticoids on lymphocyte activation in steorid-sensitive and steroid-resistant asthmatics. J Allergy Clin Immunol 98:1073-1079 (1996).
113. Anderson PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL: Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double blind study. Ann Intern Med 103: 489-496 (1985).
114. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. W Engl J Med 312: 818-822 (1985).
115. Roenig HH, Maibach HI, Weinstein G: Guidelines on methotrexate therapy for psoriasis. Arch Dermatol 105: 362-363 (1972).
116. Black RL, O'Brien WM, Van Scott EJ, Aeurbach R, Eisen AZ, Bunim JJ: Methotrexate therapy in psoriatic arthritis: Double-blind study in 21 patients. JAMA 189: 141-145 (1964).
117. Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, Wetzel CE: Methotrexate in the treatment of corticosteroid-dependent asthma. N Engl J Med 318: 603-607 (1988).
118. Shiner RJ, Nunn AJ, Chung KF, Geddes DM: Randomized, double blind, placebo controlled trial of methotrexate in steroid-dependent asthma. Lancet 336: 137-140 (1990).
119. Dyer PD, Vaughamn R, Weber RW: Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 88: 208-212 (1991).
120. Erzurum SC, Leff JA, Cochran JE, Ackerson LM, Szefler SJ, Martin RJ, Cott GR: Lack of benefit of methotrexate in severe, steroid-dependent asthma. Ann Intern Med 114: 353-360 (1991).
121. Trigg CJ, Davies RJ: Comparison of methotrexate 30 mg per week with placebo in chronic steroid-dependent asthma: a 12-week double-blind, cross-over study. Respir Med 87: 211-216 (1993).
122. Coffey MJ, Sanders G, Eschenbacher WL, Tsien A, Ramesh S, Weber RW, Toews GB, McCune WJ: The role of methotrexate in the management of steroid-dependent asthma. Chest 105: 117-121 (1994).
123. Cedes DM: Methotrexate in asthma. Clin Exp Allergy 21: 541-543 (1991).
124. Louie S, Lillington GA: Low dose methotrexate pneumonitis in rheumatoid arthritis. Thorax 41: 703-704 (1986).
125. Wallis PJW, Ryatt KS, Constable TJ: Pneumocystis carinii pneumonia complicating low dose methotrexate for psoriatic arthropathy. Ann Rheum Dis 48: 247-249 (1989).
126. Cronstein BN: Molecular mechanism of methotrexate action in inflammation. Inflammation 16: 411-423 (1992).
127. Kahan BD: Cyclosporine. N Engl J Med 321:1725-1738 (1989).
128. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegal MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG, Ellis-Madu M, Duell E, Annesley TM, Cooper KD, Voorhees JJ: Cyclosporine for plaque- type psoriasis: Results of a multidose, double-blind trial. N Engl J Med 324: 277-284 (1991).
129. Tugwell P, Bombardiere, Gent M, Bennett KJ, Benson WG, Carette S, Chalmers A, Esdaile JM, Klinkhoff AV, Kraag GR, Ludwin D, Roberts RS: Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 335:1051-1055 (1990).
130. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF: Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318: 663-670. (1988).
131. Masuda K, Urayama A, Kogure M, Nakajima A, Kimihiro N, Inaba G: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporine in Behçet's disease. Lancet 1:1093-1096 (1989).
132. Calderon E, Lockey RF, Bukantz SC, Coffey RG, Ledford DK: Is there a role for cyclosporine in asthma? J Allery Clin Immunol 89:629-636 (1992).
133. Szczeklik A, Nizankowska R, Dworski R, Domagala B, Pinis G: Cyclosporin for steroid-dependent asthma. Allergy 46: 312-315 (1991).
134. Alexander AG, Barnes NC, Kay AB: Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339: 324-328 (1992).
135. Fathman CG, Myers BD: Cyclosporine therapy for autoimmune diseases. N Engl J Med 326:1693-1695 (1992) (editorial).
136. Szczeklik A, Nizankowska E, Sladek K: Cyclosporine and asthma. Lancet 339: 873 (1992)(letter).
137. Finnerty NA, Sullivan TJ: Effect of cyclosporine on corticosteroid dependent asthma. J Allergy Clin Immunol 87: 297 (1991) (abstract).
138. Yukawa T, Arima M, Terashi Y, Sagara H, Makino S: The effect of cyclosporine A (CSA) on allergen-induced late asthmatic response (LAR) and increase of airway hyperresponsiveness (AH) in guinea pig experimental models of asthma. Am Rev Respir Dis 145: A420 (1992) (abstract).
139. Schiff RI: Intravenous gamma globulin: pharmacology, clinical uses and mechanisms of action. Pediatr Allergy Immunol 5: 63-87 (1994).
140. Bussel JB: Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenic purpura. J Allergy Clin Immunol 84: 566-578 (1989).
141. Newberger JW, Takahashi M, Burns JC, Beiser AS, Kyung JC, Duffy E, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315: 341-347 (1986).
142. Ling Z-D, Yeoh E, Webb BT, Farrell K, Doucette J, Matheson DS: Intravenous immunoglobulin induces interferon-γ and interleukin-6 in vivo. J Clin Immunol 13: 302-309 (1993).
143. Dwyer JM. Drug therapy: Manipulating the immune system with immune globulin. N Engl J Med 326: 107- 116 (1992).
144. Ballow M, White W, Desbonnet C: Modulation of in vitro synthesis of immunoglobulin and the induction of suppressor activity by therapy with intravenous immune globulin. J Allergy Clin Immunol 84: 595-602 (1989).
145. Mazer BD, Gelfand EW: An open-label study of high- dose intravenous immunoglobulin in severe child- hood asthma. J Allergy Clin Immunol 87: 976-983 (1991).
146. Spann JD, Szefler SJ, Nimmagadda SR, Gelfand EW, Leung DYM: Intravenous gammaglobulin enhances glucocorticoid sensitivity. J Allergy Clin Immunol 97: 354 (1996) (abstract).
147. Jakobsson T, Croner S, Kjellman N-IM, Pettersson A, Vassella C, Bjorksten B: Slight steroid-sparing effect of intravenous immunoglobulin in children and adolescents with moderately severe bronchial asthma. Allergy 49: 413-420 (1994).
148. Ghirga G, Ghirga P, Palazzi C, P Piero, Colaiacomo C, Presti A, Effectiveness of intravenous immunoglobulin in a 5-year old child with severe steroid-dependent asthma. Allergy 47:s197 (abstract).
149. Israel E, Rubin P, Kemp J, Grossman, Pierson W, Siegal S, Tinkelman D, Murray JJ, Busse W, Segal AT, Fish J, Kaiser HB, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen JM: The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 119:1059-1066 (1993).
150. Spector SL, Smith LJ, Glass M, and the Accolate® Asthma Trialists Group: Effects of 6 weeks of therapy with oral doses of ICI 204, 209, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 150: 618-623 (1994).